Regulatory & Legal

A regulatory filing from Balyasny Asset Management reveals intense investor activity as a bidding war for narcolepsy drugmaker Avadel heats up.

Abundia Global Impact Group and Alterra Energy are building a major plastics-to-fuel facility, a bold move to reshape the Gulf Coast's energy landscape.

A newly validated 'longevity protein' is fueling a biotech gold rush, but can companies turn breakthrough science into viable medicine? An inside look.

A $170M deal to boost infant formula supply has soured for Perrigo, leading to a 25% stock crash, a strategic review, and securities fraud lawsuits.

A $2.4B tech acquisition seems distant from healthcare, but Qualcomm's move to buy Alphawave is building the essential AI infrastructure for medicine's future.

An Atlanta clinic's top award highlights a market shift toward minimally invasive fibroid treatment and a crucial fight for health equity in women's care.

Canada's sweeping new law tackles femicide, coercive control, and online predators, aiming to shift the justice system's focus to victim protection.

Junior miner Walker Lane Resources seeks a strategic partner after permitting woes stalled its 2025 plans. Can it unlock its Nevada gold potential?

As Australia's new social media age-gate law takes effect, privacy-conscious adults are turning to VPNs to avoid sharing sensitive data with tech giants.

A strategic investment firm's move signals strong confidence in the closing of Avadel's multi-billion dollar deal, spotlighting its blockbuster sleep drug.

A new Space Force contract for real-time data processing aims to achieve "decision superiority" in an increasingly contested and dangerous orbital domain.

A 1.26% stake in Just Group, held via derivatives by Balyasny, reveals a classic merger arbitrage strategy as Brookfield's £2.4bn acquisition nears.

J.P. Morgan's 2026 outlook reveals how private markets, fueled by AI, are rebuilding the physical backbone of the global supply chain.

A new oral drug could eliminate the dangerous side effects of CAR T-Cell therapy, potentially making the breakthrough cancer treatment safer and more accessible.

Stunning trial data reveals an immunotherapy combo that slashes myeloma progression by 83%, offering not just longer life but a better quality of life.

In post-acute care, is training enough? A new digital platform aims to verify caregiver skills at the bedside, tackling both compliance and care quality.

Domestic manufacturing, massive power demands from AI and EVs, and a skilled labor shortage are converging to define a pivotal year for American industry.

With a $12M boost from a16z, Pryzm's AI is tackling the Pentagon's $900B procurement problem. Can software fix bureaucracy and secure America's edge?

Cohere Health's new Policy Studio uses AI to digitize archaic medical policies, promising to cut costs, ease provider burden, and meet new regulations.

A Texas vehicle maker is deploying its Bitcoin into regulated DeFi. Is this a risky gamble or the new blueprint for corporate finance innovation?